NCT00141284View on ClinicalTrials.gov

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
HIV InfectionHepatitis C
Interventions
DRUG

nelfinavir 1,250 mg twice daily

DRUG

Zidovudine 300 mg twice daily

DRUG

Lamivudine 150 mg twice daily

Trial Locations (5)

33136

Pfizer Investigational Site, Miami

71130

Pfizer Investigational Site, Shreveport

75390

Pfizer Investigational Site, Dallas

93301

Pfizer Investigational Site, Bakersfield

M5G 2C4

Pfizer Investigational Site, Toronto

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00141284 - An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C | Biotech Hunter | Biotech Hunter